#None #Securities Law #Faruqi & Faruqi #Zynex

Investigation of Zynex, Inc. by Faruqi & Faruqi

As investor concerns grow, Faruqi & Faruqi, LLP, a prominent national securities law firm, has taken steps to investigate Zynex, Inc. This inquiry is prompted by claims of significant financial losses sustained by investors during the abusive practices alleged against the company.

On March 28, 2025, information surfaced that urged investors who incurred losses exceeding $75,000 in Zynex between March 13, 2023, and March 11, 2025, to reach out for legal advice. Faruqi & Faruqi emphasizes the importance of acting swiftly as May 19, 2025, serves as the deadline to become the lead plaintiff in the federal securities class action filed against Zynex.

Background on Zynex

Founded with the mission to enhance health care, Zynex, Inc. (NASDAQ: ZYXI) specializes in medical devices designed for pain management and rehabilitation. However, recent scrutiny has revealed troubling allegations regarding its business practices. According to court documents, Zynex and its executives are accused of breaching federal securities laws by making misleading statements and failing to adequately disclose critical information about their business practices.

The Allegations

Investigative reports indicated alarming practices characterized by Zynex's purported oversupply of products, such as electrodes and batteries, which they allegedly provided in excess. This strategy allegedly enabled the company to inflate its revenue figures unlawfully. It has also come to light that the deceitful filing of insurance claims has caught unwanted attention from regulators and insurers, notably the military health insurance provider, Tricare.

A significant report released by the medical journal STAT on June 4, 2024, brought these issues into the public eye. This report characterized Zynex's strategy as an